The record
| Class | mitochondrial derived peptide |
|---|---|
| Also known as | HN, Humanin (wild-type) |
| Chain length | - |
| Molecular weight | 2,687 Da |
| Half-life | reported ~30 minutes (species/model dependent) |
| Route | - |
| Studied for | - |
| Research use | Cytoprotection studies, apoptosis research, neuroprotection models, metabolic disease research |
| What has been shown | Anti-apoptotic signaling in multiple cell types; Neuroprotective effects in preclinical models; Metabolic regulatory effects reported |
| How it works | Reported cytoprotective peptide with anti-apoptotic signaling; described as interacting with apoptosis-related pathways and having neuroprotective and metabolic effects in multiple models. |
| Patent status | - |
| Regulatory status | Research compound - not a standardized therapeutic |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Nerve Support / Neuro-repair Environment (affection, 46%)
- Neuroprotection Signaling (affection, 63%)
- Mitochondrial Efficiency / Energy Signaling (affection, 56%)
- Oxidative Stress Resilience (affection, 39%)
- Acetaminophen toxicity (illness, 30%)
- Age-related macular degeneration (illness, 40%)
- Antioxidant supplementation (illness, 30%)
- Barth syndrome (illness, 40%)
- Circadian rhythm disorders (illness, 40%)
- Cognitive decline (illness, 40%)
- Detoxification support (illness, 30%)
- Heart failure (illness, 40%)
- Memory impairment (illness, 40%)
- Mitochondrial myopathies (illness, 40%)
- Neuroprotection (illness, 40%)
- Skin lightening (illness, 30%)
- Fatigue or low energy (symptom, 67%)